Phio Pharmaceuticals (PHIO) Interest Coverage Ratio (2012 - 2025)
Phio Pharmaceuticals' (PHIO) quarterly Interest Coverage Ratio came in at 14.98 in Q1 2025, down 64.07% YoY from 41.68 in Q1 2024, and up 154.57% on a QoQ basis from 27.44 in Q4 2024.
Phio Pharmaceuticals (PHIO) Interest Coverage Ratio (2012 - 2025) Analysis & Trends
Phio Pharmaceuticals (PHIO) has 14 years of Interest Coverage Ratio data on file, last reported at 14.98 in Q1 2025.
- Quarterly Interest Coverage Ratio fell 64.07% year-over-year to 14.98 in Q1 2025, while the trailing twelve-month figure through Mar 2026 was 164.44 (up 177.56% YoY) and the FY2024 annual result came in at 21.92, down 416.2% from the prior year.
- Interest Coverage Ratio advanced to 14.98 in Q1 2025, from 27.44 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 957.0 in Q2 2024 to a low of 156.82 in Q4 2021.
- A 5-year average of 1.73 and a median of 79.66 in 2022 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2021 — Interest Coverage Ratio sank 813318.84% — and 2024, when it surged 1415.08%.
- Tracing PHIO's Interest Coverage Ratio over 5 years: stood at 156.82 in 2021, then surged by 48.8% to 80.29 in 2022, then jumped by 125.43% to 20.42 in 2023, then tumbled by 234.4% to 27.44 in 2024, then surged by 154.57% to 14.98 in 2025.
- The last three Interest Coverage Ratio figures came in at 14.98 (Q1 2025), 27.44 (Q4 2024), and 957.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 2.82 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.08 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.42 |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 76.86 |
| 10 | Phio Pharmaceuticals | 14.06 Mn | 14.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 14.98 |
| Dec 31, 2024 | -27.44 |
| Jun 30, 2024 | 957.00 |
| Mar 31, 2024 | 41.68 |
| Dec 31, 2023 | 20.42 |
| Sep 30, 2023 | -79.31 |
| Jun 30, 2023 | -72.77 |
| Mar 31, 2023 | -105.94 |
| Dec 31, 2022 | -80.29 |
| Sep 30, 2022 | -105.03 |
| Jun 30, 2022 | -74.15 |
| Mar 31, 2022 | -80.00 |
| Dec 31, 2021 | -156.82 |
| Sep 30, 2021 | -84.98 |
| Jun 30, 2021 | -81.33 |
| Mar 31, 2021 | -113.69 |
| Dec 31, 2020 | -0.02 |
| Sep 30, 2020 | -71.61 |
| Jun 30, 2020 | -51.83 |
| Mar 31, 2020 | -75.51 |